United Therapeutics nabs competing PAH drug with $216M SteadyMed buy
Brief:
United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in c...
Continue Reading →
